CAJ | 학술논문

目的：：探讨腹股沟皮下注射法免疫治疗小鼠变应性鼻炎( Allergic rhinitis,AR)的可行性。方法：36只雌性BALB/c小鼠,6~8周龄,随机分为6组,每组6只,包括A空白组、A模型组、A治疗组、B空白组、B模型组和B治疗组( A为腹股沟皮下注射,B为颈背部皮下注射)。卵清蛋白( Ovalbumin,OVA) AR模型建立成功后治疗组用OVA进行免疫治疗,隔天一次,共15次。鼻腔连续激发第7天时,进行小鼠 AR 症状评分,鼻黏膜变色酸2R 染色统计鼻黏膜嗜酸性粒细胞( Eosinophils,EOS)数,ELISA法检测血清OVA-sIgE表达和鼻腔灌洗液中IL-4和IFN-γ表达,计算IFN-γ与IL-4比值。以SPSS 17．0软件进行数据分析。结果：治疗前,模型组和治疗组AR症状评分均大于5,治疗后,A治疗组AR症状评分小于5。 A空白组、A模型组、A治疗组、B空白组、B模型组和B治疗组EOS数分别为0．78±0．31、21．60±2．90、10．43±2．56、0．83±0．46、22．44±3．39和23．40±4．24,A治疗组EOS数较A模型组明显减少,差异具有显著性(P<0．05),B治疗组EOS数与B模型组比较,差异无显著性(P>0．05)；空白组OVA-sIgE的表达为阴性,其余组为阳性；各组IFN-γ与IL-4比值分别为10．75±3．38、10．38±3．08、3．02±0．69、2．71±0．89、2．52±0．30和5．45±1．41,A治疗组IFN-γ与IL-4比值较A模型组明显升高,差异具有显著性意义(P<0．05),B治疗组IFN-γ与IL-4比值与B模型组比较,差异无显著性(P>0．05)。结论：腹股沟皮下注射免疫治疗小鼠变应性鼻炎效果好,周期短,操作简单,可行性好,是特异性免疫治疗小鼠变应性鼻炎的一种新方法。
목적：：탐토복고구피하주사법면역치료소서변응성비염( Allergic rhinitis,AR)적가행성。방법：36지자성BALB/c소서,6~8주령,수궤분위6조,매조6지,포괄A공백조、A모형조、A치료조、B공백조、B모형조화B치료조( A위복고구피하주사,B위경배부피하주사)。란청단백( Ovalbumin,OVA) AR모형건립성공후치료조용OVA진행면역치료,격천일차,공15차。비강련속격발제7천시,진행소서 AR 증상평분,비점막변색산2R 염색통계비점막기산성립세포( Eosinophils,EOS)수,ELISA법검측혈청OVA-sIgE표체화비강관세액중IL-4화IFN-γ표체,계산IFN-γ여IL-4비치。이SPSS 17．0연건진행수거분석。결과：치료전,모형조화치료조AR증상평분균대우5,치료후,A치료조AR증상평분소우5。 A공백조、A모형조、A치료조、B공백조、B모형조화B치료조EOS수분별위0．78±0．31、21．60±2．90、10．43±2．56、0．83±0．46、22．44±3．39화23．40±4．24,A치료조EOS수교A모형조명현감소,차이구유현저성(P<0．05),B치료조EOS수여B모형조비교,차이무현저성(P>0．05)；공백조OVA-sIgE적표체위음성,기여조위양성；각조IFN-γ여IL-4비치분별위10．75±3．38、10．38±3．08、3．02±0．69、2．71±0．89、2．52±0．30화5．45±1．41,A치료조IFN-γ여IL-4비치교A모형조명현승고,차이구유현저성의의(P<0．05),B치료조IFN-γ여IL-4비치여B모형조비교,차이무현저성(P>0．05)。결론：복고구피하주사면역치료소서변응성비염효과호,주기단,조작간단,가행성호,시특이성면역치료소서변응성비염적일충신방법。
Objective:To explore the feasibility of inguinal subcutaneous immunotherapy for allergic rhinitis ( AR ) in mice. Methods:36 female BALB/c mice were divided randomly into six groups( n=6 per group) including the control A,the model A, the treatment A groups,and the control B,the model B,the treatment B groups(inguinal subcutaneous immunotherapy for group A, cervical back subcutaneous immunotherapy for for group B). AR model was established with ovalbumin. At 25 to 55 days,ovalbumin im-munotherapy were performed in treatment groups,once two days,15 times totally. After intranasal rechallenge was performed at 56 to 62 days the AR symptom scores were documented. The eosinophils(EOS)in the nasal mucosa were measured by chromotropic acid 2R staining. Ovalbumin-specific IgE( OVA-sIgE) in the serum and expression of interferon-γ and interleukin-4 in the nasal lavage were measured by enzyme-linked immunosorbent assay meanwhile the ratio of interferon-γ and interleukin-4 was calc μlated. SPSS17. 0 software was used to analyze the data. Results:Before treatment ,the AR symptom scores of the model and treatment groups were more than 5. After treatment,the treatment A group were less than 5. The EOS count of the control A,model A,treatment A groups and the control B,model B, treatment B groups was 0. 78 ± 0. 31, 21. 60 ± 2. 90, 10. 43 ± 2. 56, 0. 83 ± 0. 46, 22. 44 ± 3. 39, 23. 40 ± 4. 24, respectively. The EOS count of the treatment A group was significantly lower than those in model A group ( P<0. 05 ) . There was no significant difference between treatment B and model B group ( P>0. 05 ) . OVA-sIgE expressed was negative in control groups and positive in other groups. The ratio of interferon-γ and interleukin-4 was 10. 75 ± 3. 38,10. 38 ± 3. 08,3. 02 ± 0. 69,2. 71 ± 0. 89,2. 52 ± 0. 30,5. 45±1. 41,respectively. The ratio in treatment A group was significantly higher than those in model A group(P<0. 05). There was no significant difference between treatment B and model B group ( P>0. 05 ) . Conclusion: Inguinal subcutaneous immunotherapy has a good effect on this disease. It spends short time ,has simple operation and good feasibility,which is a novel treatment method for AR in mice.